HTEC Acquires CertiCon Signaling Further EU Expansion and Extending MedTech, Industrial and Automotive Capabilities
5.3.2025 10:56:00 CET | Business Wire | Press Release
HTEC, the global AI-first provider of strategic services, software and hardware embedded design, and engineering expertise headquartered in San Francisco, announced today the acquisition of CertiCon a hi-tech engineering company based in the Czech Republic. CertiCon is renowned for combining applied research with technological innovation to deliver advanced digital solutions especially in medical technology, industrial production and automotive.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250305771542/en/
HTEC, a global AI-first provider of strategic services, software and hardware design, announced the acquisition of CertiCon, a hi-tech engineering company based in the Czech Republic. (Photo: Business Wire)
The acquisition will see CertiCon’s 350 experts from the Czech Republic and Slovakia join HTEC’s team of 2500 helping global companies solve complex engineering challenges to drive efficiency, reduce risk, and accelerate time to market. HTEC has a proven track record of partnering with Fortune 500 companies and together with CertiCon will partner with an even wider base of global technology leaders.
“We are excited to join forces with HTEC. The company’s vision and values are very much aligned with CertiCon’s, and we see this partnership as a unique opportunity for our team to create an even greater impact, further develop their skills, and contribute to a global technology leader. We also believe our clients will benefit from expanded capabilities and services as a result of this collaboration. For some time, we have been seeking the right partner to help propel the CertiCon story forward, and in HTEC, we are confident we have found the perfect match.” – Said Prof. Vladimir Marik, CEO and founder of CertiCon.
Both companies have succeeded in attracting exceptional talent and providing their teams with unique opportunities by engaging in developing complex new technologies for global clients.
“I am thrilled to welcome the CertiCon team on board. The company's unique culture, founded on applied research and strong collaborations with universities, represents a unique foundation to expand new opportunities to top talent in the Czech Republic and Slovakia. We are also thrilled to expand our portfolio in medical devices, industrial production, and automotive, areas of particular growth in which we can support our clients in the navigation of new technology development and the impact of AI in such highly regulated industries.” – said Aleksandar Cabrilo, co-founder and CEO of HTEC.
This acquisition has been supported by the European Bank for Reconstruction and Development (EBRD) as a longstanding partner of HTEC in expanding its international operations. It aligns with the bank’s strategy to promote the growth of the technology sector and digitization in the region.
About HTEC
HTEC Group Inc. is a global AI-first provider of strategic digital services, software design, and engineering expertise, specializing in Financial Services, MedTech, Automotive, Advanced Technologies, Telcos and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce costs, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.
About CertiCon
CertiCon is a leading provider of advanced software and hardware solutions, specializing in AI-driven informatics, applied research, and full-cycle product development. With nearly three decades of expertise, CertiCon delivers innovative work and solutions in MedTech, Industry, Automotive and Telecommunications, helping clients optimize processes, enhance efficiency, and drive digital transformation. CertiCon’s multidisciplinary teams offer end-to-end services, from research and design to development, testing, and large-scale deployment. With a strong foundation in applied research and a commitment to innovation, CertiCon collaborates with global partners to shape the future of intelligent technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305771542/en/
Contacts
For media inquiries please contact HTEC Media Relations, media@htecgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom